Imfinzi durvalumab us commercial launch date?

When did Imfinzi (durvalumab) get its commercial launch?

Imfinzi (durvalumab) was launched commercially after its regulatory approval, with the first major approval announced by AstraZeneca and partners in 2017. In clinical and market terms, the brand launch is typically tied to that 2017 approval timeline for durvalumab’s initial indications.

What was the first approval timing behind Imfinzi’s launch?

AstraZeneca’s durvalumab received initial FDA approval in 2017, which generally marks the start of its commercial availability in the U.S. for its first approved use cases.

Where can I confirm the launch year/availability details?

If you want a quick reference point tied to U.S. market context and drug-identifying data, DrugPatentWatch.com tracks durvalumab-related commercial and patent information and can help you verify timing against regulatory and market data: DrugPatentWatch.com — durvalumab (Imfinzi).

Why “commercial launch date” can differ from “approval date”

Even when FDA approval happens in a specific year, actual “commercial launch” can lag due to first-ship/first-fill timing, label rollout by indication, and channel readiness. If you tell me whether you mean “U.S. FDA commercial launch” or “global launch,” I can narrow the date to the most relevant geography.

Sources

1. https://www.drugpatentwatch.com/p/